Damora 制药

最新新闻

• 评级变动
  Leerink Partners Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Raises Target Price to $51
  \u5e02\u573a\u8d44\u8baf · 2026/5/15
• Guggenheim Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Raises Target Price to $60
  \u5e02\u573a\u8d44\u8baf · 2026/9/25
• 评级变动
  Evercore Initiates Damora Therapeutics(DMRA.US) With Buy Rating, Announces Target Price $46
  \u5e02\u573a\u8d44\u8baf · 2026/3/25
• 评级变动
  Wedbush Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Raises Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• 评级变动
  Wedbush Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/6/16
• Jefferies Initiates Damora Therapeutics(DMRA.US) With Buy Rating, Announces Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• 评级变动
  TD Cowen Initiates Damora Therapeutics(DMRA.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/8
• LifeSci Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/9/19
• 评级变动
  H.C. Wainwright Initiates Damora Therapeutics(DMRA.US) With Buy Rating, Announces Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/6/11
• 评级变动
  RBC Capital Initiates Damora Therapeutics(DMRA.US) With Buy Rating, Announces Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/4/24
• 评级变动
  RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/6/30
• Wedbush Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  A Quick Look at Today's Ratings for Damora Therapeutics(DMRA.US), With a Forecast Between $40 to $45
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  A Quick Look at Today's Ratings for Damora Therapeutics(DMRA.US), With a Forecast Between $40 to $50
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  Wedbush Initiates Damora Therapeutics(DMRA.US) With Buy Rating, Announces Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/5/28
• 评级变动
  TD Cowen Maintains Damora Therapeutics(DMRA.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/12
• 评级变动
  H.C. Wainwright Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• Guggenheim Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/6/15

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。